Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ID3-enhanced, TGFBR2-deleted GPC3-targeted CAR-iMac
- Development stage
- Preclinical
- Lead developer
- First Affiliated Hospital of Soochow University
- Modality
- Cell Therapies, Gene Therapies
- Administration
- Intraperitoneal, Intravenous
01
Overview
ID3-enhanced, TGFBR2-deleted GPC3-targeted CAR-iMac is an off-the-shelf, induced pluripotent stem cell (iPSC)-derived chimeric antigen receptor macrophage (CAR-iMac) therapy designed for the treatment of hepatocellular carcinoma (HCC). The therapy is engineered with an anti-GPC3 CAR containing the ID3 (inhibitor of DNA binding 3) transcription factor to enhance pluripotency and maintain CAR expression during myeloid differentiation. Additionally, the cells are edited using CRISPR-Cas9 to delete the TGFBR2 (transforming growth factor-beta receptor type 2) gene, rendering them resistant to the immunosuppressive effects of transforming growth factor-beta (TGF-β) in the tumor microenvironment. This dual modification promotes a pro-inflammatory M1-like phenotype, enhances tumor-cell phagocytosis, and improves infiltration and antitumor efficacy in preclinical models of HCC.
- Other names
- ID3-enhanced, TGFBR2-deleted, glypican-3 (GPC3)-targeted CAR-iMacID3-enhanced, TGFBR2-deleted, glypican-3-targeted CAR-iMac
Beyond the preview
Go deeper on ID3-enhanced, TGFBR2-deleted GPC3-targeted CAR-iMac.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ID3-enhanced, TGFBR2-deleted GPC3-targeted CAR-iMac.